In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chiesi Farmaceutici S.p.A.

https://www.chiesi.com/en/

Latest From Chiesi Farmaceutici S.p.A.

Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances

More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.

Scrip Asks Advanced Therapies

Fewer Acquisitions And Alliances In 2023, But Valuations Increased

INFOGRAPHIC: Deal volume for both M&A and alliances fell in 2023, but average valuations rose appreciably. Antibody-drug conjugates for cancer drove high-value acquisitions and partnerships.

Commercial Deals

Fewer Acquisitions And Alliances In 2023, But Valuations Increased

INFOGRAPHIC: Deal volume for both M&A and alliances fell in 2023, but average valuations rose appreciably. Antibody-drug conjugates for cancer drove high-value acquisitions and partnerships.

Scrip Perspectives Deals

Will AI Expertise Push Canada Forward As A Biopharma Hub?

In Canada, an impressive roster of machine learning companies and institutions highlights the research being conducted there. However, a paucity of VC funding and few experienced C-suite leaders has stunted the commercialization of great ideas. 

Innovation Artificial Intelligence
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Cornerstone Therapeutics (Cardiokine, Inc.
    • Critical Therapeutics, Inc.
    • EKR Therapeutics Inc.)
    • Torrex Chiesi Pharma
    • Zymenex Holding A/S
    • Atopix Therapeutics Limited
UsernamePublicRestriction

Register